Physician profile
Michael W Roppolo
NPI 1639172687
$12,801.30
in general payments reported to CMS, 2019-2025
35 companies · $5,065 in 2025
The $5,065 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $789 · 2021: $966 · 2022: $1,933 · 2023: $1,880 · 2024: $1,376 · 2025: $5,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,830 · Consulting Fee: $2,400 · Travel and Lodging: $1,070 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,830.41 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,069.63 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $5,933.23 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $1,127.03 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $1,123.11 | 2019-2025 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $918.86 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $383.23 | 2020-2024 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $362.13 | 2019-2025 | Jynarque, Voyxact |
| Medtronic, INC. | $358.83 | 2021-2023 | Ellipsys Vascular Access System |
| Bayer Healthcare Pharmaceuticals INC. | $358.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $298.90 | 2023-2025 | |
| Amgen INC. | $273.92 | 2019-2025 | Krystexxa, Tavneos |
| Baxter Healthcare | $205.80 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $185.86 | 2022-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $176.74 | 2021-2024 | Lupkynis |
| Genzyme Corporation | $152.36 | 2023 | |
| Opko Pharmaceuticals, LLC | $138.22 | 2019-2025 | Rayaldee |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $132.92 | 2023 | Benlysta |
| Nxstage Medical, INC. | $101.01 | 2022-2023 | Nxstage System One |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.25 | 2023-2025 | Jardiance |
| W. L. Gore & Associates, INC. | $66.67 | 2019 | |
| Calliditas Therapeutics US INC. | $63.58 | 2022-2023 | Tarpeyo |
| Abiomed | $60.22 | 2020 | |
| Daiichi Sankyo INC. | $56.25 | 2024 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $53.83 | 2020-2023 | |
| Ani Pharmaceuticals, INC. | $52.33 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $32.19 | 2019-2023 | Krystexxa |
| Novo Nordisk INC | $31.54 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $19.86 | 2025 | Tryvio |
| Lilly USA, LLC | $18.40 | 2024 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $15.98 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roppolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.